Stocks and Investing
Stocks and Investing
Tue, September 6, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Raghuram Selvaraju Maintained (AQST) at Strong Buy with Decreased Target to $5 on, Sep 6th, 2022
Raghuram Selvaraju of HC Wainwright & Co., Maintained "Aquestive Therapeutics, Inc." (AQST) at Strong Buy with Decreased Target from $6 to $5 on, Sep 6th, 2022.
Raghuram has made no other calls on AQST in the last 4 months.
There is 1 other peer that has a rating on AQST. Out of the 1 peers that are also analyzing AQST, 0 agree with Raghuram's Rating of Hold.
This is the rating of the analyst that currently disagrees with Raghuram
- James Molloy of "Alliance Global Partners" Initiated at Strong Buy and Held Target at $10 on, Tuesday, August 30th, 2022
Contributing Sources